Skip to main content
Fig. 6 | BMC Medicine

Fig. 6

From: The impact of blood transcriptomic biomarker targeted tuberculosis preventive therapy in people living with HIV: a mathematical modelling study

Fig. 6

Maximum cost of RISK11 test (relative to 3HP) such that the cost per case averted does not exceed the cost per case averted of universal treatment by prevalence of infection (x-axis) and annual risk of infection (y-axis). Left panel: after 5 years; right panel: after 10 years. Black dots indicate the median prevalence and ARI assumed in the CORTIS-HR cohort (Fig. 2)

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us